304 related articles for article (PubMed ID: 37452103)
1. Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome.
Salz L; Seitz A; Schäfer D; Franzen J; Holzer T; Garcia-Prieto CA; Bürger I; Hardt O; Esteller M; Wagner W
Leukemia; 2023 Sep; 37(9):1868-1878. PubMed ID: 37452103
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation changes during long-term in vitro cell culture are caused by epigenetic drift.
Franzen J; Georgomanolis T; Selich A; Kuo CC; Stöger R; Brant L; Mulabdić MS; Fernandez-Rebollo E; Grezella C; Ostrowska A; Begemann M; Nikolić M; Rath B; Ho AD; Rothe M; Schambach A; Papantonis A; Wagner W
Commun Biol; 2021 May; 4(1):598. PubMed ID: 34011964
[TBL] [Abstract][Full Text] [Related]
3. Senescence-associated DNA methylation is stochastically acquired in subpopulations of mesenchymal stem cells.
Franzen J; Zirkel A; Blake J; Rath B; Benes V; Papantonis A; Wagner W
Aging Cell; 2017 Feb; 16(1):183-191. PubMed ID: 27785870
[TBL] [Abstract][Full Text] [Related]
4. CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia.
Zebley CC; Brown C; Mi T; Fan Y; Alli S; Boi S; Galletti G; Lugli E; Langfitt D; Metais JY; Lockey T; Meagher M; Triplett B; Talleur AC; Gottschalk S; Youngblood B
Cell Rep; 2021 Nov; 37(9):110079. PubMed ID: 34852226
[TBL] [Abstract][Full Text] [Related]
5. Proof of principle: quality control of therapeutic cell preparations using senescence-associated DNA-methylation changes.
Schellenberg A; Mauen S; Koch CM; Jans R; de Waele P; Wagner W
BMC Res Notes; 2014 Apr; 7():254. PubMed ID: 24755407
[TBL] [Abstract][Full Text] [Related]
6. An epigenetic signature in CD19-CAR T cells predicts clinical outcome.
Simonetta F; Bertoni F
Trends Cancer; 2022 Feb; 8(2):81-82. PubMed ID: 34972674
[TBL] [Abstract][Full Text] [Related]
7. Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells.
You L; Han Q; Zhu L; Zhu Y; Bao C; Yang C; Lei W; Qian W
Front Immunol; 2020; 11():1787. PubMed ID: 32973749
[TBL] [Abstract][Full Text] [Related]
8. Deconvolution of cellular subsets in human tissue based on targeted DNA methylation analysis at individual CpG sites.
Schmidt M; Maié T; Dahl E; Costa IG; Wagner W
BMC Biol; 2020 Nov; 18(1):178. PubMed ID: 33234153
[TBL] [Abstract][Full Text] [Related]
9. Altered DNA methylation at age-associated CpG sites in children with growth disorders: impact on age estimation?
Mayer F; Becker J; Reinauer C; Böhme P; Eickhoff SB; Koop B; Gündüz T; Blum J; Wagner W; Ritz-Timme S
Int J Legal Med; 2022 Jul; 136(4):987-996. PubMed ID: 35551445
[TBL] [Abstract][Full Text] [Related]
10. New targeted approaches for epigenetic age predictions.
Han Y; Franzen J; Stiehl T; Gobs M; Kuo CC; Nikolić M; Hapala J; Koop BE; Strathmann K; Ritz-Timme S; Wagner W
BMC Biol; 2020 Jun; 18(1):71. PubMed ID: 32580727
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells.
Grunewald CM; Haist C; König C; Petzsch P; Bister A; Nößner E; Wiek C; Scheckenbach K; Köhrer K; Niegisch G; Hanenberg H; Hoffmann MJ
Front Immunol; 2021; 12():782448. PubMed ID: 34868059
[TBL] [Abstract][Full Text] [Related]
12. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming.
Wang Y; Tong C; Dai H; Wu Z; Han X; Guo Y; Chen D; Wei J; Ti D; Liu Z; Mei Q; Li X; Dong L; Nie J; Zhang Y; Han W
Nat Commun; 2021 Jan; 12(1):409. PubMed ID: 33462245
[TBL] [Abstract][Full Text] [Related]
13. Demonstrating the Manufacture of Human CAR-T Cells in an Automated Stirred-Tank Bioreactor.
Costariol E; Rotondi MC; Amini A; Hewitt CJ; Nienow AW; Heathman TRJ; Rafiq QA
Biotechnol J; 2020 Sep; 15(9):e2000177. PubMed ID: 32592336
[TBL] [Abstract][Full Text] [Related]
14.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
15. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
Palen K; Zurko J; Johnson BD; Hari P; Shah NN
Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
[TBL] [Abstract][Full Text] [Related]
16. Steering CAR T cell epigenetic programs by tweaking manufacturing protocol.
Dukes MW; Krenciute G
Cell Rep Med; 2023 Jun; 4(6):101080. PubMed ID: 37343521
[TBL] [Abstract][Full Text] [Related]
17. Potency monitoring of CAR T cells.
Wang D; Yang X; Xella A; Stern LA; Brown CE
Methods Cell Biol; 2023; 173():173-189. PubMed ID: 36653083
[TBL] [Abstract][Full Text] [Related]
18. Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma.
Jackson Z; Roe A; Sharma AA; Lopes FBTP; Talla A; Kleinsorge-Block S; Zamborsky K; Schiavone J; Manjappa S; Schauner R; Lee G; Liu R; Caimi PF; Xiong Y; Krueger W; Worden A; Kadan M; Schneider D; Orentas R; Dropulic B; Sekaly RP; de Lima M; Wald DN; Reese JS
Front Immunol; 2020; 11():1941. PubMed ID: 32849651
[TBL] [Abstract][Full Text] [Related]
19. Platforms for Clinical-Grade CAR-T Cell Expansion.
Mizukami A; Swiech K
Methods Mol Biol; 2020; 2086():139-150. PubMed ID: 31707673
[TBL] [Abstract][Full Text] [Related]
20. Changes to culture pH and dissolved oxygen can enhance chimeric antigen receptor T-cell generation and differentiation.
Lamas R; Ulrey R; Ahuja S; Sargent A
Biotechnol Prog; 2022 Sep; 38(5):e3275. PubMed ID: 35567431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
